Biomedical engineering

HomePage | Recent changes | View source | Discuss this page | Page history | Log in |

Printable version | Disclaimers | Privacy policy

Biomedical engineering makes medical devices, diagnostic devices, drugs and other therapies. It is more concerned with biological, safety and regulatory issues than other forms of engineering.

Most biomedical devices are either inherently safe, or have added devices and systems so that they can sense their failure and shut down into an unusuable, thus very safe state. A typical, basic requirement is that no single failure should cause the therapy to become unsafe at any point during its life-cycle. See safety engineering for a discussion of the procedures used to design safe systems.

Many biomedical devices need to be sterilized. This is a unique set of problems, as most sterilization techniques can cause damage to machinery and materials.

Most biomedical devices are completely tested. That is, every line of software is executed, or every possible setting is exercised and verified. Most devices are intentionally simplified in some way to make the testing process less expensive, yet accurate.

Regulatory issues are never far from the mind of a biomedical engineer. To satisfy regulatory issues, most biomedical systems must have documentation to show that they were managed, designed, built, tested, delivered and used using a planned, approved process. This is thought to increase the quality and safety of the therapy by reducing the likelihood that needed steps can be accidentally omitted.

Biomedical engineers operate under two basically different regulatory frameworks. These frameworks directly affect the health of citizens by affecting the development of biomedical devices.

In the U.S., the Food and Drug Administration adopts an adversarial position. It actively regulates individual devices and drugs, and assumes that new therapies are both unsafe and don't work until proven otherwise. This process is not known to prevent unsafe therapes. It is well-known to create a bottleneck in the development process, and the health effects of this bottleneck have been quantified by comparing approval times in the U.S. to approval times in Europe. The Life Extension Foundation (an interested civil action group that does not develop medical devices, see and Reason foundation (another interested civil action group that does not develop medical devices, have indpendently estimated that the FDA has killed hundreds of thousands of people, years earlier than necessary, by delaying new therapies without creating any more safety that the Eurpean system. If so, the FDA has thus destroyed more U.S. citizens' life than any war ever fought by the U.S.

In the European common market, and many other areas, regulatory organizations are licensed by the government, which inpects amd approves regulators. This is similar to the method used in the U.S. and Canada to certify electrical devices for fire-safety. If it works for fire safety, and works in Europe, it might work in the U.S.

In this system, a medical device company hires a certifyin agency to obtain approval of a biomedical device. The medical company and agency then work together to assure that the device or drug is safe. Efficacy is considered a matter for doctors and medical services to address. Consumers or their insurance company can sue both the medical device company and agency, if they can show that legal standards of safety were not met. This gives the companies reason to follow those standards.

There is no bottleneck because the regulators (who are specialized compliance engineers hired by the agency) are directly paid by the medical device company. Thus there si no shortage of qualified regulators, and less life lost to development delays.